{"id":"besifloxacin","rwe":[{"pmid":"41852520","year":"2026","title":"Besifloxacin-eluting contact lens with sustained drug delivery and enhanced bioavailability.","finding":"","journal":"International journal of pharmaceutics: X","studyType":"Clinical Study"},{"pmid":"41026985","year":"2025","title":"Hyaluronic Acid Microgels as Sequential Drug Delivery Systems.","finding":"","journal":"ACS applied bio materials","studyType":"Clinical Study"},{"pmid":"40903122","year":"2025","title":"Complexation-based spectrofluorimetric method for besifloxacin determination: Combined experimental and computational insights.","finding":"","journal":"Analytica chimica acta","studyType":"Clinical Study"},{"pmid":"40621655","year":"2025","title":"Harnessing zinc(II) chelation for fluorescence determination of besifloxacin in ophthalmic and biological matrices.","finding":"","journal":"Analytical methods : advancing methods and applications","studyType":"Clinical Study"},{"pmid":"40495004","year":"2025","title":"Structural insight in understanding the impact of mutation at position 88 and 94 of DNA gyrase A of Mycobacterium tuberculosis in developing resistance against delafloxacin.","finding":"","journal":"Journal of biological physics","studyType":"Clinical Study"}],"_fda":{"id":"1c4756f2-d92f-af5d-e063-6294a90a9a49","set_id":"a3e6d688-7e5e-4ca3-b27e-79756c322a32","openfda":{"nui":["N0000175937","M0023650"],"upc":["0324208446058"],"unii":["BFE2NBZ7NX"],"route":["OPHTHALMIC"],"rxcui":["850305","850309"],"spl_id":["1c4756f2-d92f-af5d-e063-6294a90a9a49"],"brand_name":["Besivance"],"spl_set_id":["a3e6d688-7e5e-4ca3-b27e-79756c322a32"],"package_ndc":["24208-446-05","24208-446-02"],"product_ndc":["24208-446"],"generic_name":["BESIFLOXACIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Quinolones [CS]"],"substance_name":["BESIFLOXACIN"],"pharm_class_epc":["Quinolone Antimicrobial [EPC]"],"manufacturer_name":["Bausch & Lomb Incorporated"],"application_number":["NDA022308"],"is_original_packager":[true]},"version":"20","pregnancy":["8.1 Pregnancy Risk Summary There are no available human data for the use of BESIVANCE during pregnancy to inform any drug-associated risks; however, systemic exposure to besifloxacin from ocular administration is low [see Clinical Pharmacology (12.3) ]. Oral administration of besifloxacin to pregnant rats during organogenesis or during the prenatal and postnatal period did not produce adverse embryofetal or offspring effects at clinically relevant systemic exposures [see Data]. Data Animal Data In an embryofetal development study in rats, the administration of besifloxacin at oral doses up to 1,000 mg/kg/day during organogenesis was not associated with visceral or skeletal malformations in rat fetuses, although this dose was associated with maternal toxicity (reduced body weight gain and food consumption) and maternal mortality. Increased post-implantation loss, decreased fetal body weights, and decreased fetal ossification were also observed. At this dose, the mean C max in the rat dams was approximately 20 mcg/mL, approximately 46,500 times the mean plasma concentrations measured in humans at the recommended human ophthalmic dose (RHOD). The No Observed Adverse Effect Level (NOAEL) for this embryofetal development study was 100 mg/kg/day (C max , 5 mcg/mL, approximately 11,600 times the mean plasma concentrations measured in humans at the RHOD). In a prenatal and postnatal development study in rats, the NOAELs for both fetal/neonate and maternal toxicity were 100 mg/kg/day. At 1,000 mg/kg/day, pups weighed significantly less than controls and had a reduced neonatal survival rate. Attainment of developmental landmarks and sexual maturation was delayed, although surviving pups from this dose group that were reared to maturity did not demonstrate deficits in behavior, including activity, learning and memory, and their reproductive capacity appeared normal."],"description":["11 DESCRIPTION BESIVANCE ® (besifloxacin ophthalmic suspension) 0.6% is a sterile ophthalmic suspension of besifloxacin formulated with DuraSite ® † (polycarbophil, edetate disodium dihydrate, sodium chloride, sodium hydroxide, and water for injection). Each mL of BESIVANCE contains 6.63 mg besifloxacin hydrochloride equivalent to 6 mg besifloxacin base. It is an 8-chloro fluoroquinolone anti-infective for topical ophthalmic use. C 19 H 21 ClFN 3 O 3 •HCl Molecular Weight 430.30 Chemical Name: (+)-7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride. Besifloxacin hydrochloride is a white to pale yellowish-white powder. Each mL contains: Active: besifloxacin 0.6% (6 mg/mL); Inactives: polycarbophil, mannitol, poloxamer 407, sodium chloride, edetate disodium dihydrate, sodium hydroxide, and water for injection. Preservative: benzalkonium chloride 0.01% BESIVANCE is an isotonic suspension with an osmolality of approximately 290 mOsm/kg. Besifloxacin hydrochloride structural formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING BESIVANCE ® (besifloxacin ophthalmic suspension) 0.6% is supplied as a sterile ophthalmic suspension in a white low density polyethylene (LDPE) bottle with a controlled dropper tip and beige polypropylene cap. Tamper evidence is provided with a shrink band around the cap and neck area of the package. NDC 24208-446-05 5 mL in 7.5 mL bottle Storage: Store at 15°C to 25°C (59°F to 77°F). Protect from light."],"microbiology":["12.4 Microbiology Besifloxacin is an 8-chloro fluoroquinolone with an N-1 cyclopropyl group. The compound has activity against Gram-positive and Gram-negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme required for replication, transcription and repair of bacterial DNA. Topoisomerase IV is an essential enzyme required for partitioning of the chromosomal DNA during bacterial cell division. Besifloxacin is bactericidal with minimum bactericidal concentrations (MBCs) generally within one dilution of the minimum inhibitory concentrations (MICs). The mechanism of action of fluoroquinolones, including besifloxacin, is different from that of aminoglycoside, macrolide, and β -lactam antibiotics. Therefore, besifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to besifloxacin. In vitro studies demonstrated cross-resistance between besifloxacin and some fluoroquinolones. In vitro resistance to besifloxacin develops via multiple-step mutations and occurs at a general frequency of <3.3 x 10 -10 for Staphylococcus aureus and <7 x 10 -10 for Streptococcus pneumoniae . Besifloxacin has been shown to be active against most isolates of the following bacteria both in vitro and in conjunctival infections treated in clinical trials [see Indications and Usage (1) ]: Aerococcus viridans* CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Staphylococcus warneri* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections."],"geriatric_use":["8.5 Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of BESIVANCE in infants below one year of age have not been established. The efficacy of BESIVANCE in treating bacterial conjunctivitis in pediatric patients one year or older has been demonstrated in controlled clinical trials [see Clinical Studies (14)]. There is no evidence that the ophthalmic administration of quinolones has any effect on weight-bearing joints, even though systemic administration of some quinolones has been shown to cause arthropathy in immature animals."],"effective_time":"20240703","clinical_studies":["14 CLINICAL STUDIES In a randomized, double-masked, vehicle-controlled, multicenter clinical trial, in which patients 1-98 years of age were dosed 3 times a day for 5 days, BESIVANCE was superior to its vehicle in patients with bacterial conjunctivitis. Clinical resolution was achieved in 45% (90/198) for the BESIVANCE-treated group versus 33% (63/191) for the vehicle-treated group (difference 12%, 95% CI 3% - 22%). Microbiological outcomes demonstrated a statistically significant eradication rate for causative pathogens of 91% (181/198) for the BESIVANCE-treated group versus 60% (114/191) for the vehicle-treated group (difference 31%, 95% CI 23% - 40%). Microbiologic eradication does not always correlate with clinical outcome in anti-infective trials."],"pharmacokinetics":["12.3 Pharmacokinetics Plasma concentrations of besifloxacin were measured in adult patients with suspected bacterial conjunctivitis who received BESIVANCE bilaterally three times a day (16 doses total). Following the first and last dose, the maximum plasma besifloxacin concentration in each patient was less than 1.3 ng/mL. The mean besifloxacin C max was 0.37 ng/mL on Day 1 and 0.43 ng/mL on Day 6. The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours."],"adverse_reactions":["6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The data described below reflect exposure to BESIVANCE in approximately 1,000 patients between 1 and 98 years old with clinical signs and symptoms of bacterial conjunctivitis. The most frequently reported ocular adverse reaction was conjunctival redness, reported in approximately 2% of patients. Other adverse reactions reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache. The most common adverse reaction reported in 2% of patients treated with BESIVANCE was conjunctival redness. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action Besifloxacin is a fluoroquinolone antibacterial [see Microbiology (12.4) ] ."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Besifloxacin is a fluoroquinolone antibacterial [see Microbiology (12.4) ] . 12.3 Pharmacokinetics Plasma concentrations of besifloxacin were measured in adult patients with suspected bacterial conjunctivitis who received BESIVANCE bilaterally three times a day (16 doses total). Following the first and last dose, the maximum plasma besifloxacin concentration in each patient was less than 1.3 ng/mL. The mean besifloxacin C max was 0.37 ng/mL on Day 1 and 0.43 ng/mL on Day 6. The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours. 12.4 Microbiology Besifloxacin is an 8-chloro fluoroquinolone with an N-1 cyclopropyl group. The compound has activity against Gram-positive and Gram-negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme required for replication, transcription and repair of bacterial DNA. Topoisomerase IV is an essential enzyme required for partitioning of the chromosomal DNA during bacterial cell division. Besifloxacin is bactericidal with minimum bactericidal concentrations (MBCs) generally within one dilution of the minimum inhibitory concentrations (MICs). The mechanism of action of fluoroquinolones, including besifloxacin, is different from that of aminoglycoside, macrolide, and β -lactam antibiotics. Therefore, besifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to besifloxacin. In vitro studies demonstrated cross-resistance between besifloxacin and some fluoroquinolones. In vitro resistance to besifloxacin develops via multiple-step mutations and occurs at a general frequency of <3.3 x 10 -10 for Staphylococcus aureus and <7 x 10 -10 for Streptococcus pneumoniae . Besifloxacin has been shown to be active against most isolates of the following bacteria both in vitro and in conjunctival infections treated in clinical trials [see Indications and Usage (1) ]: Aerococcus viridans* CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Staphylococcus warneri* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections."],"indications_and_usage":["1 INDICATIONS AND USAGE BESIVANCE ® (besifloxacin ophthalmic suspension) 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans* CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Staphylococcus warneri* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections. BESIVANCE ® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans *, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group , Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Not for Injection into the Eye ( Error! Hyperlink reference not valid. ) Growth of Resistant Organisms with Prolonged Use ( Error! Hyperlink reference not valid. ) Avoidance of Contact Lenses: Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE. ( 5.3 ) 5.1 Not for Injection into the Eye 5.2 Growth of Resistant Organisms with Prolonged Use As with other anti-infectives, prolonged use of BESIVANCE (besifloxacin ophthalmic suspension) 0.6% may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining. 5.3 Avoidance of Contact Lenses Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals to determine the carcinogenic potential of besifloxacin have not been performed. No in vitro mutagenic activity of besifloxacin was observed in an Ames test (up to 3.33 mcg/plate) on bacterial tester strains Salmonella typhimurium TA98, TA100, TA1535, TA1537 and Escherichia coli WP2uvrA. However, it was mutagenic in S. typhimurium strain TA102 and E. coli strain WP2 (pKM101). Positive responses in these strains have been observed with other quinolones and are likely related to topoisomerase inhibition. Besifloxacin induced chromosomal aberrations in CHO cells in vitro and it was positive in an in vivo mouse micronucleus assay at oral doses ≥1,500 mg/kg. Besifloxacin did not induce unscheduled DNA synthesis in hepatocytes cultured from rats given the test compound up to 2,000 mg/kg by the oral route. In a fertility and early embryonic development study in rats, besifloxacin did not impair the fertility of male or female rats at oral doses of up to 500 mg/kg/day. This dose is approximately 26,500 times higher than the mean plasma concentration measured in humans at the recommended human ophthalmic dose."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Handling the Container Advise patients to avoid contaminating the applicator tip with material from the eye, fingers or other source. Use with Contact Lenses Advise patients not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE. Dosing Instructions Patients should be instructed to invert closed bottle (upside down) and shake once before each use. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA Patented. See https://patents.bausch.com for US patent information. BESIVANCE is a trademark of Bausch & Lomb Incorporated or its affiliates. © 2022 Bausch & Lomb Incorporated or its affiliates † DuraSite is a trademark of Sun Pharma Global FZE. 9142709 (folded) 9142609 (flat)"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Invert closed bottle and shake once before use. Instill one drop in the affected eye(s) 3 times a day, 4 to 12 hours apart for 7 days. Instill one drop in the affected eye(s) 3 times a day, 4 to 12 hours apart for 7 days. ( 2 )"],"spl_product_data_elements":["Besivance Besifloxacin BENZALKONIUM CHLORIDE POLYCARBOPHIL MANNITOL POLOXAMER 407 SODIUM CHLORIDE EDETATE DISODIUM SODIUM HYDROXIDE WATER BESIFLOXACIN BESIFLOXACIN"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Ophthalmic suspension containing 6 mg/mL (0.6%) of besifloxacin. Ophthalmic suspension: besifloxacin 6 mg/mL (0.6%) ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available human data for the use of BESIVANCE during pregnancy to inform any drug-associated risks; however, systemic exposure to besifloxacin from ocular administration is low [see Clinical Pharmacology (12.3) ]. Oral administration of besifloxacin to pregnant rats during organogenesis or during the prenatal and postnatal period did not produce adverse embryofetal or offspring effects at clinically relevant systemic exposures [see Data]. Data Animal Data In an embryofetal development study in rats, the administration of besifloxacin at oral doses up to 1,000 mg/kg/day during organogenesis was not associated with visceral or skeletal malformations in rat fetuses, although this dose was associated with maternal toxicity (reduced body weight gain and food consumption) and maternal mortality. Increased post-implantation loss, decreased fetal body weights, and decreased fetal ossification were also observed. At this dose, the mean C max in the rat dams was approximately 20 mcg/mL, approximately 46,500 times the mean plasma concentrations measured in humans at the recommended human ophthalmic dose (RHOD). The No Observed Adverse Effect Level (NOAEL) for this embryofetal development study was 100 mg/kg/day (C max , 5 mcg/mL, approximately 11,600 times the mean plasma concentrations measured in humans at the RHOD). In a prenatal and postnatal development study in rats, the NOAELs for both fetal/neonate and maternal toxicity were 100 mg/kg/day. At 1,000 mg/kg/day, pups weighed significantly less than controls and had a reduced neonatal survival rate. Attainment of developmental landmarks and sexual maturation was delayed, although surviving pups from this dose group that were reared to maturity did not demonstrate deficits in behavior, including activity, learning and memory, and their reproductive capacity appeared normal. 8.2 Lactation Risk Summary There are no data on the presence of BESIVANCE in human milk, the effects on the breastfed infant, or the effects on milk production. However, systemic exposure to besifloxacin following topical ocular administration is low [see Clinical Pharmacology (12.3) ] , and it is not known whether measurable levels of besifloxacin would be present in maternal milk following topical ocular administration. The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for BESIVANCE, and any potential adverse effects on the breastfed infant from BESIVANCE. 8.4 Pediatric Use The safety and effectiveness of BESIVANCE in infants below one year of age have not been established. The efficacy of BESIVANCE in treating bacterial conjunctivitis in pediatric patients one year or older has been demonstrated in controlled clinical trials [see Clinical Studies (14)]. There is no evidence that the ophthalmic administration of quinolones has any effect on weight-bearing joints, even though systemic administration of some quinolones has been shown to cause arthropathy in immature animals. 8.5 Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients."],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 24208-446-05 BAUSCH + LOMB Besivance ® (besifloxacin ophthalmic Suspension) 0.6% Rx only Sterile FOR TOPICAL OPHTHALMIC USE ONLY 5 mL 9553305 AB44507 carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals to determine the carcinogenic potential of besifloxacin have not been performed. No in vitro mutagenic activity of besifloxacin was observed in an Ames test (up to 3.33 mcg/plate) on bacterial tester strains Salmonella typhimurium TA98, TA100, TA1535, TA1537 and Escherichia coli WP2uvrA. However, it was mutagenic in S. typhimurium strain TA102 and E. coli strain WP2 (pKM101). Positive responses in these strains have been observed with other quinolones and are likely related to topoisomerase inhibition. Besifloxacin induced chromosomal aberrations in CHO cells in vitro and it was positive in an in vivo mouse micronucleus assay at oral doses ≥1,500 mg/kg. Besifloxacin did not induce unscheduled DNA synthesis in hepatocytes cultured from rats given the test compound up to 2,000 mg/kg by the oral route. In a fertility and early embryonic development study in rats, besifloxacin did not impair the fertility of male or female rats at oral doses of up to 500 mg/kg/day. This dose is approximately 26,500 times higher than the mean plasma concentration measured in humans at the recommended human ophthalmic dose."]},"tags":[{"label":"Quinolone Antimicrobial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"S01AE08","category":"atc"},{"label":"Ophthalmic","category":"route"},{"label":"Suspension","category":"form"},{"label":"Active","category":"status"},{"label":"Bacterial conjunctivitis","category":"indication"},{"label":"Bausch And Lomb","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Topoisomerase II Inhibitors","category":"pharmacology"},{"label":"Topoisomerase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"EYE PAIN","source":"FDA FAERS","actionTaken":"101 reports"},{"date":"","signal":"VISION BLURRED","source":"FDA FAERS","actionTaken":"81 reports"},{"date":"","signal":"EYE IRRITATION","source":"FDA FAERS","actionTaken":"79 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"78 reports"},{"date":"","signal":"HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"68 reports"},{"date":"","signal":"OCULAR HYPERAEMIA","source":"FDA FAERS","actionTaken":"59 reports"},{"date":"","signal":"CARDIAC DISORDER","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"CHRONIC KIDNEY DISEASE","source":"FDA FAERS","actionTaken":"42 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"PHOTOPHOBIA","source":"FDA FAERS","actionTaken":"35 reports"}],"commonSideEffects":[{"effect":"Conjunctival redness","drugRate":"2%","severity":"mild","_validated":true}],"contraindications":["Superimposed infection"],"specialPopulations":{"Pregnancy":"There are no available human data for the use of BESIVANCE during pregnancy to inform any drug-associated risks; however, systemic exposure to besifloxacin from ocular administration is low. Oral administration of besifloxacin to pregnant rats during organogenesis or during the prenatal and postnatal period did not produce adverse embryofetal or offspring effects at clinically relevant systemic exposures.","Geriatric use":"No overall differences in safety and effectiveness have been observed between elderly and younger patients.","Paediatric use":"The safety and effectiveness of Besivance(TM) in infants below one year of age have not been established. The efficacy of Besivance(TM) in treating bacterial conjunctivitis in pediatric patients one year or older has been demonstrated in controlled clinical trials."}},"trials":[],"aliases":[],"company":"Bausch Health","patents":[{"applNo":"N022308","source":"FDA Orange Book","status":"Active","expires":"Nov 13, 2029","useCode":"U-80","territory":"US","drugProduct":false,"patentNumber":"8937062","drugSubstance":false},{"applNo":"N022308","source":"FDA Orange Book","status":"Active","expires":"Nov 7, 2030","useCode":"U-80","territory":"US","drugProduct":false,"patentNumber":"8415342","drugSubstance":false},{"applNo":"N022308","source":"FDA Orange Book","status":"Active","expires":"Mar 12, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8604020","drugSubstance":false},{"applNo":"N022308","source":"FDA Orange Book","status":"Active","expires":"Jan 9, 2031","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8481526","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BESIFLOXACIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:39:26.347358+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:39:26.346913+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:39:33.173951+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:39:24.883333+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BESIFLOXACIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:39:34.009393+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:23.798363+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:23.798421+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:23.798434+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:39:35.508034+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201760/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:39:34.483495+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA022308","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:23.798443+00:00"}},"allNames":"besivance","offLabel":[],"synonyms":["besifloxacin","besifloxacin hydrochloride","besivance","SS734","BOL-303224-A","besifloxacin HCl"],"timeline":[{"date":"2009-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BAUSCH AND LOMB to Bausch And Lomb"},{"date":"2009-05-28","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bausch And Lomb)"},{"date":"2031-01-09","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8481526 expires"}],"aiSummary":"Besivance (Besifloxacin) is a quinolone antimicrobial small molecule developed by Bausch and Lomb. It is used to treat bacterial conjunctivitis, a bacterial infection of the eye. Besivance is FDA-approved and remains a patented product with no generic manufacturers. Key safety considerations include potential allergic reactions and eye irritation. As a quinolone antimicrobial, Besivance works by inhibiting bacterial DNA replication.","brandName":"Besivance","ecosystem":[{"indication":"Bacterial conjunctivitis","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"ciprofloxacin","slug":"ciprofloxacin","company":"Bayer Hlthcare"},{"name":"gatifloxacin","slug":"gatifloxacin","company":"Allergan"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"Quinolone Antimicrobial [EPC]","explanation":"Besifloxacin is fluoroquinolone antibacterial [see Microbiology (12.4)].","oneSentence":"Besivance works by inhibiting bacterial DNA replication.","technicalDetail":"Besifloxacin exerts its antibacterial effect by binding to the bacterial DNA gyrase and topoisomerase IV enzymes, inhibiting DNA replication and transcription, and ultimately leading to bacterial cell death."},"commercial":{"launchDate":"2009","_launchSource":"DrugCentral (FDA 2009-05-28, BAUSCH AND LOMB)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4111","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BESIFLOXACIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BESIFLOXACIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:56:37.268533","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:39:40.534093+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"ofloxacin","drugSlug":"ofloxacin","fdaApproval":"1990-12-28","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"norfloxacin","drugSlug":"norfloxacin","fdaApproval":"1986-10-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ciprofloxacin","drugSlug":"ciprofloxacin","fdaApproval":"1987-10-22","patentExpiry":"Nov 27, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lomefloxacin","drugSlug":"lomefloxacin","fdaApproval":"1992-02-21","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"levofloxacin","drugSlug":"levofloxacin","fdaApproval":"1996-12-20","genericCount":36,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gatifloxacin","drugSlug":"gatifloxacin","fdaApproval":"2003-03-28","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"moxifloxacin","drugSlug":"moxifloxacin","fdaApproval":"1999-12-10","patentExpiry":"May 29, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"besifloxacin","indications":{"approved":[{"name":"Bacterial conjunctivitis","source":"DrugCentral","snomedId":128350005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Bausch And Lomb","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ofloxacin","brandName":"ofloxacin","genericName":"ofloxacin","approvalYear":"1990","relationship":"same-class"},{"drugId":"norfloxacin","brandName":"norfloxacin","genericName":"norfloxacin","approvalYear":"1986","relationship":"same-class"},{"drugId":"ciprofloxacin","brandName":"ciprofloxacin","genericName":"ciprofloxacin","approvalYear":"1987","relationship":"same-class"},{"drugId":"lomefloxacin","brandName":"lomefloxacin","genericName":"lomefloxacin","approvalYear":"1992","relationship":"same-class"},{"drugId":"levofloxacin","brandName":"levofloxacin","genericName":"levofloxacin","approvalYear":"1996","relationship":"same-class"},{"drugId":"gatifloxacin","brandName":"gatifloxacin","genericName":"gatifloxacin","approvalYear":"2003","relationship":"same-class"},{"drugId":"moxifloxacin","brandName":"moxifloxacin","genericName":"moxifloxacin","approvalYear":"1999","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02497365","phase":"NA","title":"Besifloxacin in Bacterial Keratitis","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-09","conditions":["Bacterial Keratitis"],"enrollment":32,"completionDate":"2019-07"},{"nctId":"NCT01296191","phase":"PHASE4","title":"Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2011-05","conditions":["Cataracts"],"enrollment":120,"completionDate":"2013-01"},{"nctId":"NCT01296542","phase":"PHASE4","title":"A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery","status":"COMPLETED","sponsor":"Bucci Laser Vision Institute","startDate":"2011-05","conditions":["Cataracts"],"enrollment":60,"completionDate":"2013-01"},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":["Keratitis; Infectious Disease (Manifestation)"],"enrollment":35,"completionDate":"2020-10"},{"nctId":"NCT04542759","phase":"PHASE1","title":"Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2017-01","conditions":["Microbial Disease","Cataract Senile"],"enrollment":60,"completionDate":"2017-04"},{"nctId":"NCT00924729","phase":"PHASE4","title":"Study of Ocular Penetration of Topically Administered Fluoroquinolones","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-09","conditions":["Cataract Extraction"],"enrollment":50,"completionDate":"2009-11"},{"nctId":"NCT01431170","phase":"PHASE1","title":"Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2011-09","conditions":["Congenital Nasolacrimal Duct Obstruction"],"enrollment":24,"completionDate":"2014-06"},{"nctId":"NCT01928693","phase":"PHASE2","title":"A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.","status":"TERMINATED","sponsor":"Cornea Consultants Of Nashville","startDate":"2013-07","conditions":["Corneal Ulcers"],"enrollment":2,"completionDate":"2014-05"},{"nctId":"NCT00348348","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":["Acute Bacterial Conjunctivitis"],"enrollment":1161,"completionDate":"2007-07"},{"nctId":"NCT00347932","phase":"PHASE3","title":"A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":["Acute Bacterial Conjunctivitis"],"enrollment":957,"completionDate":"2007-11"},{"nctId":"NCT00622908","phase":"PHASE2","title":"Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2004-12","conditions":["Bacterial Conjunctivitis"],"enrollment":270,"completionDate":"2005-06"},{"nctId":"NCT01740388","phase":"PHASE3","title":"Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis","status":"TERMINATED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-02","conditions":["Bacterial Conjunctivitis"],"enrollment":136,"completionDate":"2013-11"},{"nctId":"NCT01330355","phase":"PHASE3","title":"Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis","status":"TERMINATED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-05","conditions":["Bacterial Conjunctivitis"],"enrollment":33,"completionDate":"2013-10"},{"nctId":"NCT01478256","phase":"PHASE4","title":"Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis","status":"COMPLETED","sponsor":"John, George, M.D.","startDate":"2011-08","conditions":["Blepharitis"],"enrollment":30,"completionDate":"2011-10"},{"nctId":"NCT01175590","phase":"PHASE3","title":"Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-06","conditions":["Bacterial Conjunctivitis"],"enrollment":518,"completionDate":"2012-02"},{"nctId":"NCT01120418","phase":"PHASE1","title":"Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-05","conditions":["Healthy"],"enrollment":120,"completionDate":"2008-02"},{"nctId":"NCT01193504","phase":"PHASE4","title":"Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification","status":"UNKNOWN","sponsor":"Innovative Medical","startDate":"2010-09","conditions":["Pseudophakia","Cataract Surgery"],"enrollment":100,"completionDate":"2012-10"},{"nctId":"NCT00972777","phase":"PHASE2,PHASE3","title":"Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-10","conditions":["Bacterial Conjunctivitis"],"enrollment":474,"completionDate":"2011-02"},{"nctId":"NCT00824070","phase":"PHASE1","title":"Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":["Cataract Extraction"],"enrollment":105,"completionDate":"2009-08"},{"nctId":"NCT00407589","phase":"PHASE1","title":"Systemic Pharmacokinetics of BOL-303224-A","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-10","conditions":["Conjunctivitis, Bacterial"],"enrollment":24,"completionDate":"2007-10"},{"nctId":"NCT00905762","phase":"PHASE1","title":"Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-03","conditions":["Healthy"],"enrollment":119,"completionDate":"2009-04"},{"nctId":"NCT01455233","phase":"PHASE4","title":"2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery","status":"COMPLETED","sponsor":"Ophthalmology Consultants, Ltd.","startDate":"2010-09","conditions":["Corneal Health","Cataract Surgery"],"enrollment":60,"completionDate":"2011-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Suspension","formulations":[{"form":"SUSPENSION","route":"OPHTHALMIC","productName":"Besivance"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000178482","MMSL":"165190","NDDF":"013123","UNII":"BFE2NBZ7NX","VUID":"4028790","CHEBI":"CHEBI:135622","VANDF":"4028790","INN_ID":"8958","RXNORM":"819911","UMLSCUI":"C2351042","chemblId":"CHEMBL1201760","ChEMBL_ID":"CHEMBL1201760","KEGG_DRUG":"D08872","DRUGBANK_ID":"DB06771","PUBCHEM_CID":"10178705","SNOMEDCT_US":"442870007","SECONDARY_CAS_RN":"405165-61-9","MESH_SUPPLEMENTAL_RECORD_UI":"C522124"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2009-","companyName":"Bausch And Lomb","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","fractionUnbound":"0.391%"},"publicationCount":125,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"S01AE08","allCodes":["S01AE08"]},"biosimilarFilings":[],"originalDeveloper":"Bausch And Lomb","recentPublications":[{"date":"2026 Jun","pmid":"41852520","title":"Besifloxacin-eluting contact lens with sustained drug delivery and enhanced bioavailability.","journal":"International journal of pharmaceutics: X"},{"date":"2025 Oct 20","pmid":"41026985","title":"Hyaluronic Acid Microgels as Sequential Drug Delivery Systems.","journal":"ACS applied bio materials"},{"date":"2025 Oct 22","pmid":"40903122","title":"Complexation-based spectrofluorimetric method for besifloxacin determination: Combined experimental and computational insights.","journal":"Analytica chimica acta"},{"date":"2025 Jul 17","pmid":"40621655","title":"Harnessing zinc(II) chelation for fluorescence determination of besifloxacin in ophthalmic and biological matrices.","journal":"Analytical methods : advancing methods and applications"},{"date":"2025 Jun 10","pmid":"40495004","title":"Structural insight in understanding the impact of mutation at position 88 and 94 of DNA gyrase A of Mycobacterium tuberculosis in developing resistance against delafloxacin.","journal":"Journal of biological physics"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Bausch And Lomb","companyId":"bausch","modality":"Small molecule","firstApprovalDate":"2009","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-04-30T00:00:00.000Z","mah":"BAUSCH AND LOMB","brand_name_local":null,"application_number":"NDA022308"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:39:40.534093+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}